Like nucleic-acid drugs, protein drugs that contain such cytokine as interferon (IFN-α), interleukin, granulocyte colony stimulating factor (G-CSF) and growth factor also need to have stability in the bloodstream in order to have therapeutic efficacy.

With micellar nanoparticles technology, NanoCarrier aims to develop protein micelles that have longer half-life in bloodstream (slow release), improved therapeutic efficacy and lower side effects. Particle size and release rate of drugs can be optimized to meet each application needs.